Prism Medico & Pharmacy Ltd
₹ 18.2
4.97%
12 Dec
- close price
About
Incorporated in 1985, Prism Medico & Pharmacy Ltd manufactures, trades, and distributes chemicals, medicines, pharmaceuticals, cosmetics, and related products[1]
Key Points
- Market Cap ₹ 11.0 Cr.
- Current Price ₹ 18.2
- High / Low ₹ 26.3 / 11.6
- Stock P/E 18.0
- Book Value ₹ 24.9
- Dividend Yield 0.00 %
- ROCE -0.40 %
- ROE -0.33 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.73 times its book value
Cons
- The company has delivered a poor sales growth of -52.8% over past five years.
- Promoter holding is low: 25.0%
- Company has a low return on equity of -0.34% over last 3 years.
- Company has high debtors of 2,074 days.
- Working capital days have increased from 4,885 days to 8,551 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.09 | 0.09 | 20.96 | 36.31 | 26.89 | 16.76 | 8.44 | 1.27 | 2.93 | 0.63 | 2.37 | |
| 0.05 | 0.06 | 0.15 | 0.37 | 20.86 | 35.98 | 26.94 | 16.92 | 8.93 | 1.37 | 3.06 | 0.71 | 1.82 | |
| Operating Profit | -0.05 | -0.06 | -0.06 | -0.28 | 0.10 | 0.33 | -0.05 | -0.16 | -0.49 | -0.10 | -0.13 | -0.08 | 0.55 |
| OPM % | -66.67% | -311.11% | 0.48% | 0.91% | -0.19% | -0.95% | -5.81% | -7.87% | -4.44% | -12.70% | 23.21% | ||
| 0.00 | 0.06 | 0.06 | 0.07 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.02 | 0.03 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.01 | 0.01 | 0.02 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Profit before tax | -0.05 | -0.01 | -0.01 | -0.23 | 0.05 | 0.29 | -0.07 | -0.17 | -0.50 | -0.11 | -0.03 | -0.06 | 0.58 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 140.00% | -24.14% | -28.57% | -29.41% | -26.00% | -27.27% | -33.33% | -33.33% | |
| -0.05 | -0.01 | -0.01 | -0.23 | -0.02 | 0.37 | -0.05 | -0.13 | -0.37 | -0.08 | -0.02 | -0.05 | 0.61 | |
| EPS in Rs | -0.25 | -0.05 | -0.05 | -0.38 | -0.03 | 0.61 | -0.08 | -0.21 | -0.61 | -0.13 | -0.03 | -0.08 | 1.01 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -53% |
| 3 Years: | -58% |
| TTM: | -27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | 23% |
| TTM: | 1425% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -8% |
| 3 Years: | -4% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.99 | 1.99 | 1.99 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 |
| Reserves | -0.35 | -0.36 | -0.36 | 6.74 | 6.72 | 7.09 | 6.99 | 6.86 | 6.49 | 9.10 | 9.08 | 9.03 |
| 0.00 | 0.02 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.02 | 0.04 | 0.16 | 0.25 | 0.16 | 3.82 | 8.54 | 8.63 | 0.02 | 0.23 | 0.10 | 0.47 | |
| Total Liabilities | 1.66 | 1.69 | 1.86 | 13.05 | 12.94 | 16.97 | 21.59 | 21.55 | 12.57 | 15.39 | 15.24 | 15.56 |
| 0.02 | 0.01 | 0.00 | 0.16 | 0.11 | 0.09 | 0.07 | 0.06 | 0.05 | 0.03 | 0.03 | 0.03 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 10.00 | 11.25 | 10.00 | 1.94 | 1.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| 1.64 | 1.68 | 1.86 | 2.89 | 1.58 | 6.88 | 19.58 | 19.55 | 12.52 | 15.36 | 15.21 | 15.53 | |
| Total Assets | 1.66 | 1.69 | 1.86 | 13.05 | 12.94 | 16.97 | 21.59 | 21.55 | 12.57 | 15.39 | 15.24 | 15.56 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | 0.01 | 0.05 | -0.82 | -0.06 | -1.23 | -4.36 | -0.05 | -2.38 | 2.95 | -0.01 | -0.02 | |
| 0.03 | 0.00 | 0.46 | 0.30 | -1.25 | 1.25 | 4.36 | 0.02 | 2.35 | -2.91 | 0.00 | 0.00 | |
| 0.00 | 0.02 | 0.05 | 1.33 | -0.05 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | |
| Net Cash Flow | 0.00 | 0.02 | 0.56 | 0.81 | -1.36 | 0.08 | -0.01 | -0.03 | -0.03 | 0.04 | -0.01 | -0.02 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365.00 | 0.00 | 0.00 | 37.80 | 248.94 | 294.22 | 211.04 | 1,368.03 | 459.68 | 2,074.13 | ||
| Inventory Days | 0.00 | 15.75 | 9.95 | 965.25 | 5,491.22 | |||||||
| Days Payable | 0.00 | 37.02 | 4.28 | 0.00 | ||||||||
| Cash Conversion Cycle | 365.00 | 0.00 | 15.75 | 10.73 | 248.94 | 294.22 | 211.04 | 1,368.03 | 1,420.65 | 7,565.35 | ||
| Working Capital Days | 4,177.22 | 5,069.44 | 25.08 | 29.65 | 148.36 | 234.99 | 530.20 | 4,259.29 | 1,844.93 | 8,551.43 | ||
| ROCE % | -3.00% | -0.61% | -0.60% | -3.17% | 0.47% | 4.01% | -0.53% | -1.31% | -3.93% | -0.79% | -0.13% | -0.40% |
Documents
Announcements
-
Revised Outcome Of The Board Meeting Held On 14Th November, 2025.
21 Nov - Board approved unaudited Q2/H1 results for September 30, 2025; PDF reuploaded correcting missing statements.
-
Board Meeting Outcome for Outcome Of The Board Meeting - Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
14 Nov - Board approved unaudited standalone Q2 and H1 results ended 30 Sep 2025; limited review dated 14 Nov 2025.
-
Board Meeting Intimation for Intimation Of Board Meeting.
6 Nov - Board meeting on 14 Nov 2025 to approve unaudited Q2/H1 results for period ended 30 Sep 2025.
-
Undertaking Of Functional Website.
27 Oct - Website updated and functional at https://www.prismmedico.in per Regulation 46 (dated 27.10.2025).
-
Investor Complaints As Per Regulation 13(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
17 Oct - No investor complaints for quarter ended 30 September 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
PMPL deals in chemicals, serums, chemical products, antibiotics, medicines, drugs,
pharmaceuticals, pesticides, dyes, soaps, oils, perfumes, cosmetics, patent medicines, etc.